untitled design

Prevent Senior doctor says he would go back to prescribing hydroxychloroquine

Physician Rodrigo Esper, responsible for the Prevent Senior study on the use of hydroxychloroquine in the treatment of Covid-19, said this Thursday (11), in a statement to the CPI at the São Paulo City Council, that he “would have to talk to the person”, but that, possibly, would still prescribe drugs without proven efficacy to patients.

According to him, this would happen “off label” and is part of the “medical freedom” he defends.

Despite the statement, the doctor denied that he had made guinea pig patients: “There has never been any kind of experimentation”, and that the company has concealed deaths.

Regarding the study carried out on the use of hydroxychloroquine, Esper stated that it was something “just observational”, not having been published in any scientific journal.

In addition to Rodrigo Esper, the São Paulo councilors heard Rafael de Souza da SILva, current clinical director who reports to the telemedicine department of the operator, Dr. Sérgio Antônio Dias da Silveira, and Daniella Cabral de Freitas, current clinical director of Prevent Senior.

During the testimony, the doctor, who would have signed the Covid-19 Clinical Management Protocol, prepared by the operator, said that all patients who took ineffective medications signed “consent terms”, which goes against the complaints that were received by the CPI

At the end of the testimonies, in an interview with the press, the councilors who make up the commission classified the testimonies as “ineffective”, and regretted that “until today the company adopts the same posture as the beginning of the pandemic”.

This was the fifth session of the CPI. Next week, the testimony of a health surveillance representative is confirmed: “we still have a lot to clarify, for example, to understand why hospitals operated without permits”, added the president of the commission Antônio Donato (PT).

Reference: CNN Brasil

You may also like

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular